ATM and breast cancer: To test whether the association of CHEK2 mutation with poor outcome observed in breast cancer extends to other cancer types preferentially in women, we conducted a gender-stratified Kaplan-Meier analysis of disease-specific survival and somatic mutations in ATM and CHEK2 across solid cancers.